Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...
CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER UNDER A LICENSING AGREEM ...
Inhibiting GLS1 reduced high blood pressure in the right side of the heart of PAH rats and improved various measures of heart ...